Companies /Healthcare

Boston Scientific Corp

NYSE: BSX Medical Devices
$48.30
â–² $1.46 (+3.12%) today
Markets closed · 7:22pm ET

Q2 2025 Earnings

Reported Jul 23, 2025, 6:32am ET · SEC source
$0.75
Beat +2.74%
EPS · est. $0.73
$5.1B
Beat +3.39%
Revenue · est. $4.9B
−3.2%
Trailing market
BSX vs S&P since report
6 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
0+2%+4%Jul 23Jul 24report 6:32am ETearnings+0.5%+2.5%
0+2%+4%Jul 23Jul 24earnings+0.5%+2.5%
BSX +2.5%S&P 500 +0.5%
0+2%+4%Jul 23Jul 24report 6:32am ETearnings+0.4%+2.5%
0+2%+4%Jul 23Jul 24earnings+0.4%+2.5%
BSX +2.5%NASDAQ +0.4%
0+2%+4%Jul 22Jul 31report 6:32am ETearnings+1.3%+3.5%
0+2%+4%Jul 22Jul 31earnings+1.3%+3.5%
BSX +3.5%S&P 500 +1.3%
0+2%+4%Jul 22Jul 31report 6:32am ETearnings+2.2%+3.5%
0+2%+4%Jul 22Jul 31earnings+2.2%+3.5%
BSX +3.5%NASDAQ +2.2%
+4.46%
Day of report
−1.44%
Next session
−0.93%
One week
−1.48%
30 days

S&P 500 over the same 30 days: +1.75%.

Did BSX Beat Earnings? Q2 2025 Results

Boston Scientific delivered a standout second quarter, posting adjusted EPS of $0.75 against a consensus estimate of $0.73, a beat of 3.42%, while revenue of $5.06 billion topped the $4.89 billion estimate by 3.39% and grew 22.8% year over year. The primary engine behind the quarter was the Cardiovascular segment, which surged 26.8% on a reported basis, driven by Cardiology growth of 29.3% and bolstered by FDA approval to expand the FARAPULSE PFA System labeling to include persistent atrial fibrillation, a key regulatory catalyst that reinforced the company's position in cardiac rhythm management. MedSurg contributed meaningfully as well, with Urology alone advancing 28.9%. Geographically, U.S. growth of 30.7% led all regions. With momentum firmly in hand, Boston Scientific raised its full-year 2025 outlook to 18 to 19 percent reported growth and adjusted EPS of $2.95 to $2.99, while guiding Q3 adjusted EPS to $0.70 to $0.72, signaling continued confidence in the durability of its growth trajectory.

Key Takeaways
  • Exceptional Cardiovascular segment growth of 26.8%, driven by Cardiology (29.3%) and Peripheral Interventions (18.3%)
  • U.S. sales growth of 30.7% year-over-year
  • Urology business grew 28.9% on a reported basis
  • Organic net sales growth of 17.4%, significantly exceeding guidance of 13 to 15 percent
  • Margin expansion alongside investment prioritization for future growth

“This was another excellent quarter — marked by exceptional top-line performance — that delivered margin expansion and prioritized investment for future growth.”

Boston Scientific CEO, on the earnings call

Forward Guidance & Outlook

For full year 2025, Boston Scientific estimates net sales growth of approximately 18 to 19 percent on a reported basis and 14 to 15 percent on an organic basis. Full year GAAP EPS is estimated at $1.89 to $1.93, with adjusted EPS of $2.95 to $2.99. For Q3 2025, the company estimates net sales growth of approximately 17 to 19 percent on a reported basis and 12 to 14 percent on an organic basis, with GAAP EPS of $0.44 to $0.46 and adjusted EPS of $0.70 to $0.72.

BSX YoY Financials

Q2 2025 vs Q2 2024 · SEC filings Q2 2024 Q2 2025
$0$2.0B$4.0B$4.1B$5.1BRevenue$2.6B$3.4BGross Profit$747.0M$819.0MOperating Income$324.0M$797.0MNet Income
$0$2.0B$4.0BRevenueGross ProfitOperating IncomeNet Income

BSX Revenue by Segment

Cardiovascular$3.3B+26.8%
Cardiology$2.6B+29.3%
MedSurg$1.7B+15.7%
Endoscopy$737.0M+9.1%
Urology$676.0M+28.9%
Peripheral Interventions$698.0M+18.3%
Neuromodulation$303.0M+7.2%

BSX Revenue by Geography

United States$3.2B+30.7%
EMEA$878.0M+6.8%
Asia Pacific$790.0M+18.0%
Latin America$169.0M+4.0%

Figures from SEC filings and company reports. Not investment advice.